Halozyme Therapeutics Overview
Latest ROE for Halozyme Therapeutics: 288.13% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow288.13%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Halozyme Therapeutics's return on equity stands at 288.13%. That is above the Healthcare sector average of 21.67%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Halozyme Therapeutics sits higher the Healthcare benchmark (21.67%) with a ROE of 288.13%. That is roughly 1229.8% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
A ROE of 288.13% for Halozyme Therapeutics means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.
The history chart shows how Halozyme Therapeutics's ROE evolved across reporting periods, while the comparison chart places HALO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, ROE is commonly used to spot outliers. Halozyme Therapeutics's reading of 288.13% (sector avg 21.67%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.
